Articles - Page 31 of 69 - Drugs in Context

Psoriasis, biologic therapy, and the pandemic of the 21st century

Miguel Nogueira MD, Ron Vender MD, Tiago Torres MD, PhD

Article Type

Editorial

Published

14 May 2020

This editorial discusses the impact of COVID-19 on patients with psoriasis receiving biologic agents.

Facing the COVID-19 outbreak in children with cancer

Antonio Ruggiero MD, Alberto Romano MD, Giorgio Attinà MD

Article Type

Editorial

Published

12 May 2020

This editorial discusses the current COVID-19 outbreak and underlines that hygienic educational programs are fundamental and must be continued and implemented especially for immunosuppressed children.

Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?

Louise Statham MPharm, PGClin Dip, PGCHE, IPresc, Sharon Abdy RN, BSc (Hons), Terry J Aspray MBBS, MD, FRCP, FRCP(Edinburgh)

Article Type

Original Research

Published

08 May 2020

The aim of this study was to analyse changes in C-terminal telopeptide on stopping long-term blood pressures in a real-world population to see whether
persistence of BP effect was maintained.

Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature

Luis Miguel Juárez-Salcedo MD, Diego Conde-Royo MD, Keina Quiroz-Cervantes MD, Samir Dalia MD

Article Type

Review

Published

06 May 2020

This article discusses the role of mAbs in follicular lymphoma and marginal zone lymphoma along with reviewing the current data about the use of biosimilar mAbs in these diseases.

Conjunctivitis in patients with atopic dermatitis treated with dupilumab

Sandra Ferreira MD, Tiago Torres MD, PhD

Article Type

Review

Published

04 May 2020

The present paper reviews the data of dupilumab-associated conjunctivitis and risk factors in adults with moderate-to-severe AD and other atopic diseases in dupilumab clinical trials and addresses the characteristics and treatment options available for this clinically highly relevant condition.